Hépato-Gastro & Oncologie Digestive


Ce qui change nos pratiques dans la prise en charge des cancers gastriques Volume 26, numéro 8, Octobre 2019

  • [1] Cunningham D., Allum W., Stenning S. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
  • [2] Ychou M., Boige V., Pignon J.P. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721.
  • [3] Mary F., Zaanan A., Boige V. AGEO (Association des Gastro-Ent.rologues Oncologues). Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Dig Liver Dis. 2016;48:1498-1502.
  • [4] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet 2019 ; 393 (10184) : 1948-1957.
  • [5] Al-Batran S.E., Hofheinz R.D., Pauligk C. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): Results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17:1697-1708. 12
  • [6] Messager M., Lefevre J.H., Pichot-Delahaye V. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: A multicenter comparative study. Ann Surg. 2011;254:684-693. 5
  • [7] Eveno C, Adenis A, Bouche O, et al. Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric. J Clin Oncol 2019;(37, no. 15 suppl.) : 4019-4019.
  • [8] https://www.has-sante.fr/portail/jcms/c_2892234/fr/des-recommandations-pourprevenir-certaines-toxicites-severes-des-chimiotherapies-par-fluoropyrimidines.
  • [9] Zaanan A, Bouché O, Benhaim L, et al. Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis 2018 ; 50 (8) : 768-79.
  • [10] Bang Y.J., Van Cutsem E., Feyereislova A. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687-697. 9742
  • [11] Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 2018 ; 19 (10) : 1372-84.
  • [12] Palle J., Tougeron D., Pozet A. Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: A multicenter AGEO study. Oncotarget. 2017;8:101383-101393. 60
  • [13] Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): An international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 2017 ; 18 (5) : 640-53.
  • [14] Makiyama A., Sagara K., Kawada J. A randomized phase II study of weekly paclitaxel 6 trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum : WJOG7112G (T-ACT). J Clin Oncol. 2018;36:4011-14011. 15 suppl.
  • [15] Shitara K, Doi T, Dvorkin M, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018 ; 19 (11) : 1437-1448.
  • [16] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017 ; 390 (10111) : 2461-2471.
  • [17] Muro K., Chung H.C., Shankaran V. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): A multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717-726. 6
  • [18] Fuchs C.S., Doi T., Jang R.W. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013. 5
  • [19] Bang YJ, Ruiz EY, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 2018 ; 29 (10) : 2052-2060.
  • [20] Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 2018 ; 392 (10142) : 123-133.
  • [21] Tabernero J, Van Cutsem E, Bang Y-J, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol 2019 ; 37 (15 Suppl.) : LBA4007.
  • [22] Kohlruss M, Grosser B, Krenauer M, et al. Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: Role of Epstein-Barr virus infection and high- and low-microsatellite instability. J Pathol Clin Res 2019 Jun 17. doi : 10.1002/cjp2.137.[Epub ahead of print].
  • [23] Giampieri R., Maccaroni E., Mandolesi A. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20:156-163. 1
  • [24] Le D.T., Uram J.N., Wang H. PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520. 26
  • [25] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017 ; 357 (6349) : 409-13.
  • [26] Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018 ; 36 (28) : 2836-44.